REV-OBESITY: A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study with Open-Label Extension to Assess the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Taldefgrobep alfa in Adults Living with Overweight and Obesity.

Study Purpose: Learn about the efficacy, safety, and tolerability of taldefgrobep as a potential treatment for weight management in adults living with overweight/obesity, and to better understand how taldefgrobep moves through your body and how your body responds to taldefgrobep. To be enrolled in this study, you must meet certain requirements. You may be eligible to participate if you meet the following criteria: Study Duration: 60-week period Study Commitment: 16 in-person/office visits and 1 virtual (phone) Age: 18-65 years old Sex: Male & Female Conditions/Eligibility: Male or female, 18-65 years old living with overweight and obesity Study Procedures: Physical exam, vital signs, height, weight, BMI, screening labs, urine screen, measurement of waist and hip circumference, EKG DEXA MRI Medical and medication history Camera recording of your body measurements. Diet and exercising counseling Multiple blood draws Questionnaires Sit to stand test Compensation: up to $1,720.00 with an additional $450 with the MRI substudy